Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying causes of thrombosis and type one diabetes. By leveraging a deep understanding of the molecular mechanisms associated with these conditions, the company seeks to create innovative treatment options that can lead to improved health outcomes for patients. Their focus includes therapies specifically targeting heparin-induced thrombocytopenia and thrombosis, with the goal of providing patients with effective solutions for complete recovery from diabetes and associated complications.
Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients.
Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
IDbyDNA, Inc. is a company based in Salt Lake City, Utah, founded in 2014, that specializes in metagenomics technologies aimed at the identification of infectious diseases. The company has developed a platform called Explify, which assists laboratories in detecting pathogens through nucleic acid-based identification from various samples. IDbyDNA's offerings include advanced software that utilizes computational biology and artificial intelligence for sequencing-based pathogen detection and characterization. Additionally, the company provides testing services, including respiratory and research services, catering to a diverse clientele that encompasses hospitals, reference labs, clinical research institutions, and the biopharma sector. The overall mission of IDbyDNA is to empower clinicians and researchers with the tools needed to identify any pathogen efficiently, thereby enhancing the capability for comprehensive infectious disease profiling in a streamlined workflow.
EBT Medical, Inc. is a clinical-stage company focused on developing non-invasive neuromodulation therapies for pelvic health disorders, particularly targeting overactive bladder issues. Founded in 2014 and headquartered in Boston, Massachusetts, with an additional office in Toronto, Canada, the company emerged from scientific research conducted at the University of Toronto. EBT Medical's innovative technology aims to provide discreet treatment options that restore pelvic health function without the side effects commonly associated with traditional therapies. The company is part of a broader ecosystem designed to support patients with pelvic floor disorders.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients.
Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.
Adapsyn Bioscience is a owner and operator of a biotechnology company intended to focus on the identification and characterization of microorganism-derived small molecules, to uncover chemical agents possessing novel biological activities relevant to the biotechnology and pharmaceutical sectors. The company's services is supported by cutting-edge bioinformatic software platforms and state of the art laboratory facilities, enabling researchers to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better protect users from a wide spectrum of diseases.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Therapeutic Monitoring Systems Inc. develops and commercializes bedside point-of-care clinical decision support software that improves patient care in the hospital ICU and emergency department. It offers CIMVA software platform for physicians and nurses to improve how care is delivered. The company’s CIMVA software integrates with critical care monitors to analyze patient vital signs for offering insights into a patient’s health status currently unavailable. Therapeutic Monitoring Systems Inc. also provides CIMVA Universal, a Web-based application that allows physicians and nurses to calculate and display changes in physiological waveform variability in multiple-organ systems or multi-parameters in a single organ system. The company serves customers in the United States and internationally. Therapeutic Monitoring Systems Inc. was founded in 2007 and is based in Ottawa, Canada.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Profound Medical Corp. is a medical technology company that specializes in the development of magnetic resonance guided ablation procedures for treating conditions such as prostate disease, uterine fibroids, and palliative pain from bone metastases. The company's lead product, the TULSA-PRO system, combines real-time MRI guidance with robotically driven ultrasound to provide precise, non-invasive tissue ablation. This system is designed to work seamlessly with existing MRI infrastructure in hospitals and treatment facilities. Additionally, Profound Medical offers the Sonalleve platform, which targets uterine fibroids and bone metastases. The company is headquartered in Mississauga, Canada, and has established a co-development agreement with GE Healthcare to enhance access to its TULSA-PRO system. Profound Medical is committed to improving patient care by providing safe and effective treatment options that allow for quicker recovery and a return to daily activities.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
Invitae is a genetic information company focused on integrating genetic testing into routine medical practice to enhance healthcare quality worldwide. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates a wide array of genetic tests into one platform, ensuring faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's test offerings cover various hereditary conditions, including cancers, neurological disorders, cardiovascular diseases, pediatric and metabolic disorders. The company aims to make genetic testing more affordable and accessible, develop a secure infrastructure for genome management, and foster a global community for sharing genetic information to advance scientific research and medical practices. By lowering the barriers to obtaining diagnostic genetic information, Invitae seeks to improve healthcare outcomes for millions of individuals.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.
Functional Neuromodulation is a medical technology company that specializes in developing neuromodulation therapies aimed at treating Alzheimer's disease and other cognitive disorders. Established in 2010, the company is headquartered in Toronto, Canada, with an additional office in Minneapolis, Minnesota. Its primary offering is a deep brain stimulation (DBS) technology, which involves a surgically implanted device that delivers mild electrical pulses to specific areas of the brain. This approach is designed to enhance neural activity and modulate memory circuits, ultimately assisting patients in managing symptoms associated with memory and cognitive impairments. Through its innovative therapies, Functional Neuromodulation aims to improve the quality of life for individuals suffering from these challenging conditions.
gIcare Pharma Inc. is a biopharmaceutical start-up established in 2011 and based in Montreal, Canada, specializing in the development of innovative gastrointestinal drugs. The company focuses on addressing unmet medical needs in the field of gastroenterology, aiming to create medicines that not only benefit patients but also offer clinical advantages to healthcare providers and economic benefits to payers. gIcare's flagship drug candidate, GIC-1001, exemplifies this approach by integrating multiple levels of benefits, reflecting the company's commitment to advancing healthcare solutions in gastrointestinal medicine.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.
Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.
NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.
Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.
Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, focused on developing and commercializing implantable medical devices and skeletal tissue regeneration products, primarily for orthopedic applications in the United States and Europe. The company offers Skelite, a synthetic bone graft designed for healing and replacement, as well as Primacoll and Peptos, which are products aimed at stimulating bone tissue growth. Additionally, Millenium Biologix has developed ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering. Established in 1986, the company continues to innovate in the field of orthopedics.
StemPath develops therapeutic solutions for modulating body's natural regenerative capacity and endogenously replacing damaged tissues with new tissues by intervention with small molecule and biological drugs. It focuses on cardiac and skeletal muscle myopathies. The company was founded in 2002 and is based in Ottawa, Canada.
NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.